Clinical trials
Myasthenia Gravis clinical trials
Below are recruiting myasthenia gravis clinical trials, each written for real people, not researchers. We’re tracking 97 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT07478172Recruiting
Electrical muscle stimulation exercise for neuromuscular disease
This study tests whether whole-body electrical muscle stimulation (using small electrodes on the skin) can help adults with certain neuromuscular diseases exercise and improve muscle strength. It may be an option if you can stand for about 15 minutes at a time and have some muscle strength left.
Columbia, MissouriAges 18 years+ - NCT07470151Recruiting
Study of EVM18001 for hard-to-treat autoimmune diseases
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
Wuhan, HubeiAges 18–70 - NCT07411963Recruiting
Early ravulizumab for severe myasthenia gravis crisis in the ICU
This study tests whether starting ravulizumab early, after plasma exchange or IVIg, can help people with a severe myasthenia gravis crisis who are in the intensive care unit. It aims to see if it improves their condition.
Nice, Alpes-maritimesAges 18 years+ - NCT07337785RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
Wuhan, HubeiAges 18–70 - NCT07304154RecruitingPhase 1
Study of KITE-363 for autoimmune nerve diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune nerve diseases, such as multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy, that have not responded well to standard therapies. The goal is to see if it is safe and effective.
Newport Beach, CaliforniaAges 18–75 - NCT07215949RecruitingPhase 3
Zilucoplan for severe myasthenia gravis flare-ups
This trial tests zilucoplan, a daily injection, to treat severe muscle weakness from myasthenia gravis that requires hospital care. It may help you recover faster and avoid needing a breathing tube.
Tampa, FloridaAges 18 years+ - NCT07089121RecruitingPhase 1/Phase 2
Descartes-08 for young people with autoimmune diseases
This trial tests a new therapy called Descartes-08 for children, teens, and young adults with autoimmune conditions like lupus, myasthenia gravis, or dermatomyositis. It aims to see if it can help control moderate disease that hasn't responded well enough to other treatments.
Washington D.C., District of ColumbiaAges 12 years+ - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT07022197RecruitingPhase 1/Phase 2
BAFF-R CAR T cells for severe nerve and immune diseases
This trial tests a new treatment using your own immune cells (called BAFF-R CAR T cells) for people with severe nerve and immune diseases that have not improved with standard medicines. These cells are designed to target and destroy certain immune cells that may be causing your illness.
Tianjin, Tianjin MunicipalityAges 18–60 - NCT06879210Recruiting
AI in precision medicine for myasthenia gravis
This trial uses artificial intelligence to help personalize care for people with myasthenia gravis. It may offer insights into better treatment options tailored to you.
New Taipei City, Tamsui DistrictAges 20 years+ - NCT06939166RecruitingEarly Phase 1
Immune cell therapy for relapsed neurological autoimmune diseases
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06940323Recruiting
Pregnancy study for women with chronic conditions
This study tracks pregnant women with certain chronic health conditions (like multiple sclerosis, lupus, or rheumatoid arthritis) and healthy pregnant women as a comparison group. It aims to understand how these conditions and their treatments affect pregnancy, the baby, and breast milk.
San Francisco, CaliforniaAges 18–64 - NCT06877403Enrolling by invitation
Fatigue study in myasthenia gravis patients
This study looks at how common and how severe fatigue is in people with myasthenia gravis. It aims to understand the impact of fatigue on daily life and may help improve care for patients with this condition.
Clermont-FerrandAges 18 years+ - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06064461Recruiting
Myasthenia gravis patient registry study
This study is a patient registry that tracks the experiences of people with myasthenia gravis over time. It aims to better understand the condition and improve care, using a smartphone, tablet, or computer to share information.
Orange, CaliforniaAges 18 years+ - NCT06743490Recruiting
Tracking MG symptoms with smartphone recordings
This study uses your smartphone to record symptoms like slurred speech, hoarseness, arm fatigue, or droopy eyelids, making it easier for doctors to understand and monitor myasthenia gravis. Both people with MG and healthy volunteers can take part.
Leiden, South HollandAges 18 years+ - NCT06455709Recruiting
Markers predicting response to complement inhibitor therapy
This study looks for markers that may predict a favorable response to complement inhibitor drugs in people with generalized myasthenia gravis. It aims to identify who might benefit most from this treatment.
RomaAges 18 years+ - NCT06626919RecruitingPhase 1
A cell therapy trial for generalized myasthenia gravis
This trial tests a new cell therapy called anitocabtagene autoleucel (anito-cel) for people with generalized myasthenia gravis (gMG) that is not well controlled with current treatments. The goal is to see if it can reduce symptoms and improve quality of life.
Los Angeles, CaliforniaAges 18 years+ - NCT06605612Enrolling by invitation
Falls risk test for people with muscle and nerve conditions
This study is creating a test to predict falls in people with neuromuscular disorders. You will fill out a questionnaire about your fall risk.
München, BavariaAges 18–65 - NCT06502015Recruiting
Biomarkers in nervous system autoimmune diseases
This study looks for biomarkers (biological clues) in people with autoimmune diseases of the nervous system. It aims to discover better ways to diagnose and treat these conditions.
WuhanAges 18 years+ - NCT06298565Recruiting
Safety study of efgartigimod for generalized myasthenia gravis
This study looks at how safe efgartigimod is for people with generalized myasthenia gravis (gMG), whether they are taking the drug now, will start it soon, or are not taking it at all.
San Francisco, CaliforniaAges 18 years+ - NCT06299748Recruiting
Efgartigimod safety study for pregnancy and breastfeeding
This study is for women who have taken efgartigimod (a medicine for certain autoimmune conditions) right before or during pregnancy, or while breastfeeding. Researchers will monitor moms, fetuses, and babies to check for side effects and ensure safety.
Morgantown, West VirginiaAges Any age - NCT06312644Recruiting
Study of Ultomiris safety during pregnancy
This study looks at the safety of the medication Ultomiris when taken during pregnancy or breastfeeding. If you are pregnant and currently taking Ultomiris for an approved condition, this research will help gather information on how it affects you and your baby.
Boston, MassachusettsAges Any age
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myasthenia gravis?
- Yes. Clin2 currently lists 97 recruiting myasthenia gravis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myasthenia gravis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myasthenia gravis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.